- The DOVETAIL phase 1 trial evaluated vamikibart, an intravitreal anti–interleukin-6 monoclonal antibody, for noninfectious uveitic macular edema.
- No drug-related serious adverse events, sustained intraocular pressure elevations, or new cataracts were reported across dose groups.
- One patient experienced worsening uveitis that resolved after 75 days and was considered unrelated to the study drug.
- Mean best-corrected visual acuity improvements of 10.7 and 9.0 letters were observed in the two lower dose groups.
- More than 80% of participants achieved complete resolution of intraretinal fluid by week 12.
- Improvements in anterior chamber inflammation and vitreous haze suggested potential anti-inflammatory effects beyond macular edema reduction.
- Researchers emphasized that the small, nonrandomized design without a control group prevents conclusions regarding efficacy or causality.
Vamikibart Shows Early Safety in Uveitic Macular Edema
Conexiant
May 7, 2026
